Ikarian Capital, LLC
Reported holdings as of Q2 2026, from 27 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ABIVAX SA OPT | ABVX | $122.1M | 328,635 | +10.00pp | 4q | +470.2%+$100.7M | |
| IONIS PHARMACEUTICALS INC OPT | IONS | $55.5M | options only | +4.52pp | 4q | OPTIONS | |
| KODIAK SCIENCES INC OPT | KOD | $49.8M | 1,059,730 | +1.13pp | 14q | -16.3%-$9.7M | |
| SPDR SERIES TRUST OPT | XBI | $47.5M | options only | -3.18pp | 4q | OPTIONS | |
| ALUMIS INC OPT | ALMS | $34.5M | 870,548 | +1.08pp | 3q | -28.3%-$13.6M | |
| PRAXIS PRECISION MEDICINES I OPT | PRAX | $31.4M | 72,842 | +1.51pp | 6q | +1.8%+$543.3K | |
| MODERNA INC OPT | MRNA | $28.0M | options only | - | new | OPTIONS | |
| CAPRICOR THERAPEUTICS INC OPT | CAPR | $23.0M | 604,215 | +0.31pp | 8q | +14.4%+$2.9M | |
| VAXCYTE INC | PCVX | $22.6M | 388,682 | +0.41pp | 6q | -9.3%-$2.3M | |
| ANI PHARMACEUTICALS INC | ANIP | $22.5M | 272,085 | +0.57pp | 3q | +85.0%+$10.3M | |
| CELLDEX THERAPEUTICS INC NEW OPT | CLDX | $22.0M | 478,500 | +0.89pp | 2q | +3.7%+$794.9K | |
| TENAX THERAPEUTICS INC OPT | TENX | $17.1M | 787,600 | +0.38pp | 4q | -22.6%-$5.0M | |
| VERA THERAPEUTICS INC OPT | VERA | $16.4M | 310,000 | +0.88pp | 2q | +55.0%+$5.8M | |
| ARCUS BIOSCIENCES INC | RCUS | $15.6M | 504,559 | - | new | NEW | |
| RELMADA THERAPEUTICS INC | RLMD | $14.9M | 2,148,359 | +0.08pp | 22q | -20.1%-$3.7M | |
| COGENT BIOSCIENCES INC | COGT | $14.3M | 370,084 | - | new | NEW | |
| NEWAMSTERDAM PHARMA COMPANY OPT | NAMS | $13.6M | options only | - | new | OPTIONS | |
| CONTINEUM THERAPEUTICS INC | CTNM | $13.2M | 807,874 | +0.57pp | 3q | HELD | |
| C4 THERAPEUTICS INC | CCCC | $11.4M | 2,433,000 | - | new | NEW | |
| MAZE THERAPEUTICS INC | MAZE | $11.3M | 378,999 | +0.27pp | 6q | HELD | |
| ARROWHEAD PHARMACEUTICALS IN OPT | ARWR | $11.3M | 38,278 | +0.92pp | 2q | HELD | |
| BIOHAVEN LTD | BHVN | $11.1M | 748,181 | +0.92pp | 3q | +81.4%+$5.0M | |
| CONNECT BIOPHARMA HLDGS LTD | CNTB | $10.8M | 4,538,534 | +0.07pp | 3q | -15.8%-$2.0M | |
| ALTO NEUROSCIENCE INC | ANRO | $10.7M | 407,338 | +0.22pp | 8q | -20.9%-$2.8M | |
| PHARVARIS N V | PHVS | $10.7M | 308,856 | +0.03pp | 4q | -36.6%-$6.2M | |
| EYEPOINT INC OPT | EYPT | $10.6M | options only | +0.37pp | 2q | OPTIONS | |
| JADE BIOSCIENCES INC | JBIO | $9.5M | 427,349 | +0.44pp | 3q | -16.6%-$1.9M | |
| DAMORA THERAPEUTICS INC | DMRA | $8.7M | 335,710 | +0.23pp | 3q | HELD | |
| Q32 BIO INC OPT | QTTB | $8.0M | 430,000 | - | new | NEW | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $7.8M | 425,000 | - | new | NEW | |
| OLEMA PHARMACEUTICALS INC OPT | OLMA | $7.3M | 383,281 | -0.60pp | 3q | -35.9%-$4.1M | |
| PELTHOS THERAPEUTICS INC | PTHS | $7.3M | 256,598 | +0.34pp | 4q | HELD | |
| ZURA BIO LTD | ZURA | $7.2M | 1,218,492 | +0.20pp | 4q | +2.1%+$147.5K | |
| TECTONIC THERAPEUTIC INC | TECX | $7.1M | 205,837 | +0.37pp | 2q | +30.7%+$1.7M | |
| SPRUCE BIOSCIENCES INC | SPRB | $6.6M | 121,356 | +0.06pp | 4q | HELD | |
| HIMS & HERS HEALTH INC | HIMS | $6.5M | 188,381 | - | new | NEW | |
| ENLIVEN THERAPEUTICS INC | ELVN | $6.4M | 126,541 | +0.43pp | 2q | HELD | |
| PROQR THRAPEUTICS N V | PRQR | $6.4M | 3,425,930 | +0.49pp | 5q | +129.6%+$3.6M | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $6.2M | 88,951 | -0.31pp | 7q | -46.6%-$5.5M | |
| OVID THERAPEUTICS INC | OVID | $6.1M | 2,269,704 | +0.14pp | 4q | -21.6%-$1.7M | |
| OCUGEN INC | OCGN | $6.1M | 3,962,972 | +0.07pp | 2q | HELD | |
| ALPHA COGNITION INC | ACOG | $6.0M | 836,259 | +0.18pp | 7q | -20.8%-$1.6M | |
| KYMERA THERAPEUTICS INC OPT | KYMR | $5.8M | options only | +0.28pp | 2q | OPTIONS | |
| HARROW INC | HROW | $5.8M | 135,775 | -0.93pp | 4q | -75.0%-$17.3M | |
| KAZIA THERAPEUTICS LTD | KZIA | $5.6M | 396,201 | - | new | NEW | |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | $5.5M | 165,617 | -0.23pp | 8q | -65.7%-$10.6M | |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | $5.4M | 809,741 | -0.14pp | 3q | -33.3%-$2.7M | |
| SELLAS LIFE SCIENCES GROUP I OPT | SLS | $5.2M | options only | - | new | OPTIONS | |
| BIOAGE LABS INC | BIOA | $4.9M | 200,000 | - | new | NEW | |
| REZOLUTE INC | RZLT | $4.9M | 935,012 | +0.52pp | 3q | +5574.0%+$4.8M | |
| SIONNA THERAPEUTICS INC OPT | SION | $4.7M | options only | - | new | OPTIONS | |
| MONOPAR THERAPEUTICS INC | MNPR | $4.4M | 47,861 | - | new | NEW | |
| BRIDGEBIO PHARMA INC | BBIO | $4.3M | 57,417 | -0.86pp | 2q | -64.1%-$7.6M | |
| INVENTIVA SA | IVA | $4.2M | 1,129,101 | -0.19pp | 3q | -21.0%-$1.1M | |
| ABSCI CORPORATION | ABSI | $4.1M | 353,772 | - | new | NEW | |
| ALECTOR INC | ALEC | $4.0M | 1,982,606 | +0.07pp | 7q | -4.8%-$201.0K | |
| CLIMB BIO INC | CLYM | $3.9M | 300,000 | - | new | NEW | |
| FULCRUM THERAPEUTICS INC | FULC | $3.8M | 1,049,161 | -0.24pp | 8q | HELD | |
| CARDIOL THERAPEUTICS INC | CRDL | $3.5M | 3,325,000 | +0.08pp | 2q | +22.0%+$636.0K | |
| CUE BIOPHARMA INC | CUE | $3.3M | 104,364 | - | new | NEW | |
| CUMBERLAND PHARMACEUTICALS I | CPIX | $3.3M | 503,153 | +0.21pp | 6q | -9.0%-$324.0K | |
| REIN THERAPEUTICS INC | RNTX | $3.1M | 2,950,000 | - | new | NEW | |
| ARVINAS INC | ARVN | $3.0M | 358,257 | +0.01pp | 6q | HELD | |
| ACUMEN PHARMACEUTICALS INC | ABOS | $2.8M | 1,053,797 | +0.10pp | 16q | HELD | |
| PROMIS NEUROSCIENCES INC | PMN | $2.7M | 205,000 | +0.23pp | 2q | +272.7%+$2.0M | |
| ANNEXON INC | ANNX | $2.5M | 430,244 | flat | 3q | -25.9%-$856.5K | |
| BRISTOL-MYERS SQUIBB CO OPT | BMY | $2.4M | options only | -2.20pp | 2q | OPTIONS | |
| LEXEO THERAPEUTICS INC | LXEO | $2.4M | 513,011 | +0.02pp | 8q | HELD | |
| DELCATH SYS INC | DCTH | $2.3M | 185,667 | -0.07pp | 9q | -56.9%-$3.1M | |
| INVIVYD INC | IVVD | $2.3M | 2,656,570 | -0.03pp | 4q | HELD | |
| UNIQURE NV OPT | QURE | $2.3M | options only | -0.22pp | 5q | OPTIONS | |
| CABALETTA BIO INC | CABA | $2.2M | 700,000 | +0.04pp | 3q | -22.2%-$622.0K | |
| NEUMORA THERAPEUTICS INC. | NMRA | $2.2M | 1,278,408 | +0.03pp | 8q | HELD | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $2.1M | 117,500 | - | new | NEW | |
| TARSUS PHARMACEUTICALS INC | TARS | $2.0M | 31,166 | +0.03pp | 12q | HELD | |
| DISC MEDICINE INC OPT | IRON | $1.9M | options only | - | new | OPTIONS | |
| SILENCE THERAPEUTICS PLC | SLN | $1.8M | 830,784 | +0.06pp | 5q | -4.0%-$77.0K | |
| JOURNEY MED CORP | DERM | $1.8M | 251,436 | +0.10pp | 3q | HELD | |
| DBV TECHNOLOGIES S A | DBVT | $1.7M | 525,000 | flat | 3q | HELD | |
| IBIO INC | IBIO | $1.7M | 957,062 | +0.03pp | 10q | HELD | |
| AVALO THERAPEUTICS INC | AVTX | $1.7M | 90,183 | -0.50pp | 10q | HELD | |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $1.6M | 166,571 | +0.01pp | 2q | -54.6%-$2.0M | |
| PALISADE BIO INC | PALI | $1.6M | 750,000 | +0.13pp | 3q | +172.7%+$992.8K | |
| AMANAT ACQUISITION CORP | AMAN | $1.5M | 150,000 | - | new | NEW | |
| KALARIS THERAPEUTICS INC | KLRS | $1.5M | 360,000 | -0.01pp | 3q | HELD | |
| QUINCE THERAPEUTICS INC | $1.3M | 72,251 | - | new | NEW | ||
| LIPOCINE INC NEW | LPCN | $1.3M | 508,556 | -0.19pp | 3q | HELD | |
| IMMUNOME INC | IMNM | $1.3M | 60,000 | - | new | NEW | |
| ELICIO THERAPEUTICS INC OPT | ELTX | $1.2M | 100,000 | - | new | NEW | |
| PLIANT THERAPEUTICS INC | PLRX | $1.1M | 1,000,000 | - | new | NEW | |
| IMMUNIC INC | IMUX | $1.0M | 67,464 | - | new | NEW | |
| QUOIN PHARMACEUTICALS LTD | QNRX | $1.0M | 211,538 | flat | 3q | HELD | |
| EQUILLIUM INC | EQ | $971.4K | 303,555 | +0.06pp | 4q | HELD | |
| NEURONETICS INC | STIM | $911.5K | 701,182 | +0.02pp | 6q | HELD | |
| FAETH THERAPEUTICS INC | FTH | $884.6K | 35,386 | +0.08pp | 5q | +457.2%+$725.9K | |
| FRACTYL HEALTH INC | GUTS | $873.8K | 1,100,000 | +0.05pp | 4q | HELD | |
| CYBIN INC | HELP | $873.5K | 132,153 | +0.04pp | 8q | HELD | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $860.6K | 42,775 | - | new | NEW | |
| VERASTEM INC | VSTM | $817.0K | 213,865 | flat | 3q | HELD | |
| DIREXION SHARES ETF TRUST | LABD | $815.9K | 105,822 | -0.05pp | 4q | HELD | |
| PEPGEN INC | PEPG | $804.9K | 447,165 | -0.02pp | 6q | HELD | |
| ACADIA PHARMACEUTICALS INC | ACAD | $710.9K | 28,099 | +0.03pp | 2q | HELD | |
| CNS PHARMACEUTICALS INC | CNSP | $649.3K | 135,830 | +0.06pp | 3q | +196.4%+$430.2K | |
| LYELL IMMUNOPHARMA INC | LYEL | $577.2K | 41,081 | flat | 5q | HELD | |
| WAVE LIFE SCIENCES LTD | WVE | $495.5K | 85,285 | flat | 5q | HELD | |
| IMMATICS N.V | IMTX | $492.0K | 48,569 | +0.01pp | 5q | HELD | |
| PASSAGE BIO INC | PASG | $485.6K | 99,517 | +0.01pp | 2q | +46.1%+$153.2K | |
| NEXTCURE INC | NXTC | $461.3K | 288,303 | -0.15pp | 3q | +21.0%+$80.0K | |
| FORTE BIOSCIENCES INC | FBRX | $445.7K | 20,972 | -0.20pp | 7q | -82.4%-$2.1M | |
| SOLID BIOSCIENCES INC | SLDB | $429.1K | 42,956 | -0.11pp | 4q | -83.8%-$2.2M | |
| TRAWS PHARMA INC | TRAW | $403.2K | 478,142 | -0.06pp | 7q | -29.5%-$168.7K | |
| LEXICON PHARMACEUTICALS INC | LXRX | $395.2K | 164,674 | +0.02pp | 7q | HELD | |
| ADLAI NORTYE LTD | ANL | $389.8K | 33,899 | +0.02pp | 2q | HELD | |
| INMED PHARMACEUTICALS INC | INM | $379.8K | 245,025 | - | new | NEW | |
| VIKING THERAPEUTICS INC | VKTX | $379.1K | 9,717 | +0.02pp | 6q | HELD | |
| MACROGENICS INC | MGNX | $346.0K | 74,893 | +0.02pp | 10q | HELD | |
| HYPERLIQUID STRATEGIES INC | PURR | $236.1K | 30,001 | +0.01pp | 3q | HELD | |
| EVAXION AS | EVAX | $231.6K | 74,698 | flat | 6q | HELD | |
| CARTESIAN THERAPEUTICS INC | RNAC | $216.8K | 20,807 | +0.01pp | 9q | HELD | |
| COMPASS PATHWAYS PLC | CMPS | $212.2K | 15,000 | -0.28pp | 4q | -97.8%-$9.3M | |
| NEUPHORIA THERAPEUTICS INC | NEUP | $207.3K | 47,443 | +0.01pp | 3q | HELD | |
| VOYAGER THERAPEUTICS INC | VYGR | $185.7K | 53,063 | flat | 13q | HELD | |
| VYNE THERAPEUTICS INC | VYNE | $172.4K | 264,912 | +0.01pp | 5q | HELD | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $167.6K | 16,756 | - | new | NEW | |
| ENVERIC BIOSCIENCES INC | ENVB | $138.0K | 100,002 | - | new | NEW | |
| PMV PHARMACEUTICALS INC | PMVP | $119.4K | 89,136 | flat | 4q | HELD | |
| VISTAGEN THERAPEUTICS INC | VTGN | $117.3K | 519,077 | -0.01pp | 7q | HELD | |
| CHEMOMAB THERAPEUTICS LTD | CMMB | $83.9K | 51,793 | flat | 4q | HELD | |
| NYXOAH S A | NYXH | $80.0K | 47,358 | flat | 5q | HELD | |
| AIRSCULPT TECHNOLOGIES INC | AIRS | $73.8K | 16,398 | flat | 5q | HELD | |
| MANGOCEUTICALS INC | MGRX | $52.5K | 138,146 | flat | 3q | HELD | |
| COMPASS THERAPEUTICS INC | CMPX | $39.4K | 18,000 | flat | 3q | HELD | |
| THERIVA BIOLOGICS INC | TOVX | $28.0K | 112,076 | flat | 6q | HELD | |
| GLUCOTRACK INC | GCTK | $14.6K | 45,830 | flat | 3q | HELD | |
| AETHLON MED INC | AEMD | $11.8K | 14,364 | flat | 3q | HELD | |
| JASPER THERAPEUTICS INC | JSPR | $10.1K | 24,093 | flat | 10q | HELD | |
| BIOMX INC | PHGE | $6.8K | 19,473 | -0.01pp | 3q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $863.2M | 93.0% |
| Other sectors | $12.8M | 1.4% |
| Not classified | $52.2M | 5.6% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $928.2M | 137 | 29 | 18 | 30 | 31 | 47.1% | 45 |
| Q1 2026 | $1.2B | 139 | 24 | 27 | 18 | 33 | 49.7% | 45 |
| Q4 2025 | $1.3B | 148 | 47 | 26 | 62 | 38 | 44.8% | 49 |
| Q3 2025 | $990.4M | 139 | 48 | 22 | 33 | 23 | 43.8% | 45 |
| Q2 2025 | $520.6M | 114 | 25 | 14 | 27 | 52 | 47.4% | 45 |
| Q1 2025 | $811.5M | 141 | 35 | 23 | 33 | 41 | 60.6% | 45 |
| Q4 2024 | $735.3M | 147 | 47 | 16 | 25 | 21 | 46.1% | 45 |
| Q3 2024 | $717.2M | 121 | 40 | 8 | 30 | 14 | 48.1% | 45 |
| Q2 2024 | $574.1M | 95 | 17 | 13 | 24 | 22 | 57.9% | 45 |
| Q1 2024 | $912.0M | 100 | 26 | 22 | 29 | 27 | 45.7% | 47 |
| Q4 2023 | $1.1B | 101 | 26 | 7 | 15 | 32 | 46.7% | 45 |
| Q3 2023 | $831.4M | 107 | 38 | 25 | 24 | 25 | 53.1% | 45 |
| Q2 2023 | $627.9M | 94 | 32 | 11 | 21 | 35 | 52.7% | 45 |
| Q1 2023 | $440.7M | 97 | 36 | 9 | 19 | 11 | 47.9% | 45 |
| Q4 2022 | $414.5M | 72 | 9 | 8 | 24 | 19 | 59.7% | 45 |
| Q3 2022 | $501.8M | 82 | 27 | 7 | 42 | 58 | 52.0% | 45 |
| Q2 2022 | $548.4M | 113 | 21 | 13 | 40 | 77 | 52.6% | 43 |
| Q1 2022 | $760.5M | 169 | 19 | 123 | 11 | 16 | 50.9% | 43 |
| Q4 2021 | $671.3M | 166 | 25 | 9 | 46 | 32 | 49.8% | 45 |
| Q3 2021 | $1.4B | 173 | 39 | 18 | 102 | 43 | 44.9% | 46 |
| Q2 2021 | $1.2B | 177 | 21 | 26 | 55 | 82 | 40.8% | 49 |
| Q1 2021 | $3.0B | 238 | 86 | 36 | 47 | 31 | 37.8% | 140 |
| Q4 2020 | $2.3B | 183 | 74 | 22 | 36 | 28 | 48.4% | 43 |
| Q3 2020 | $1.4B | 137 | 52 | 20 | 30 | 41 | 46.7% | 47 |
| Q2 2020 | $1.3B | 126 | 41 | 12 | 33 | 30 | 41.0% | 45 |
| Q1 2020 | $1.3B | 115 | 48 | 21 | 9 | 24 | 55.3% | 45 |
| Q4 2019 | $617.2M | 91 | 0 | 0 | 0 | 0 | 52.1% | 31 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.